There is limited experience of ondansetron overdose.
Because of its ability to increase liver enzyme levels, ondansetron should be used cautiously in patients with impaired liver function.
The dose range of ondansetron solution for injection or infusion is 8-32 mg a day and selected as shown below. However, as animal studies are not always predictive of human response, the use of ondansetron in pregnancy is not recommended. In addition to the adverse reactions listed above, the following adverse reactions have been described in the setting of ondansetron overdose Sudden blindness amaurosis of 2 to 3 minutes duration plus severe constipation occurred in one patient that was administered 72 mg of ondansetron intravenously as a single dose.
Before using this medication, tell your doctor or pharmacist your medical history, especially of irregular heartbeat, liver disease, stomach intestinal problems e. Ondansetron is in a class of medications called serotonin 5-HT 3 receptor antagonists.
Ask your doctor before use if you are taking the following medications:
This finding suggests the need to understand better the appropriate clinical variables that need to be assessed before patients step down from combination therapy.
In patients who show severe intolerance to the recommended dose, treatment may be continued at a lower dose with the consequences of a longer therapy duration and a higher risk of relapse.
Sometimes too much yeast starts to grow in the vagina and this can cause a yeast infection.
Do not use another dose from the Diskus if you do not feel or taste the medicine.
People who take this medication for a long time or at high doses are at an increased risk of heart attack, stroke, and blood clots.
In summary, we wish to call the attention of physicians, nurses, and pharmacists to the instability of concentrated solutions of ondansetron in an alkaline environment. The safety of ondansetron for use in human pregnancy has not been established. The dosage for children may also be based on age and weight. Cases of transient blindness, predominantly during intravenous administration, have been reported.